Categories: All postsCannabis

Canopy Growth Corp. is simply “unrivalled” following Constellation Brands investment: GMP

Following the headline grabbing news that beverage giant Constellation Brands would invest five-billion (Canadian) dollars into Canopy Growth Corp. (TSX:WEED, NYSE:CGC) the latter is unrivalled in terms of its ability to capture market share globally, says GMP Securities analyst Martin Landry.

On Wednesday, it was announced that liquor giant Constellation Brands would invest (US) $4-billion into Canopy by acquiring 104.4-million shares, giving it 38 per cent ownership of the Smiths Falls firm.

“Through this investment, we are selecting Canopy Growth as our exclusive global cannabis partner,” Constellation Brands CEO Rob Sands said of the deal. “Over the past year, we’ve come to better understand the cannabis market, the tremendous growth opportunity it presents, and Canopy’s market-leading capabilities in this space. We look forward to supporting Canopy as they extend their recognized global leadership position in the medical and recreational cannabis space.”

Landry says this investment put the company on another level, but don’t expect Canopy to immediately go on a spending spree.

“With a war chest of more than $5b, Canopy’s ability to capture the global cannabis opportunity is unrivalled,” he says. “While we don’t think the company will deploy all this capital near-term, Canopy has the financial flexibility to expand in the US, a market which could see significant legislative changes in the coming years. Hence, this new cash infusion clears the road for significant expansion and drastically changes the company’s growth profile. Canopy appears to have the undisputed leadership position in the global cannabis industry, which warrants a valuation premium vs peers in our view. Canopy’s proforma cash balance of $5.8b represent ~$13.50/share or 30% of WEED’s share price.”

In a research update to clients Thursday, Landry maintained his “Buy” rating, but raised his one-year price target on Canopy Growth Corp. from $40.00 to $50.00, implying a return of 18.5 per cent at the time of publication.

The analyst thinks WEED will post EBITDA of negative $500,000 on revenue of $468.8-million in fiscal 2019. He expects those numbers will improve to EBITDA of $246.1-million on a topline of $1.08-billion the following year.

Landry says this move is all about preparing for a sea-change in the United States.

“It is clear that Canopy wants to expand in the U.S. where they believe legislation could change sooner than later,” he says. “The company wants to be ready on day one and with its $5b war chest, is in a solid position to acquire strategic assets and rapidly become a leader. At maturity, the US market could generate US$50b in annual sales, thereby significantly increasing Canopy’s addressable market.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: weed
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

1 day ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 day ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago